Clinical Trials on Pancreatic Cancer in China

Total 7334 results

Shanghai Zhongshan Hospital
Fudan University

Not yet recruiting

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

Pancreatic Cancer Stage III | Pancreatic Cancer, Stage IB | Pancreatic Cancer, Stage IIA | Pancreatic Cancer, Stage IIB

China
RenJi Hospital
Ruijin Hospital; Shanghai General Hospital, Shanghai Jiao Tong University School...

Unknown

An Open-label, Multicenter, Prospective Study of Irreversible Electroporation (Nano Knife) Combined With Radiotherapy and Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

Pancreatic Cancer | Locally Advanced Pancreatic Caner

China
Tianjin Medical University Cancer Institute and...

Unknown

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer (HST)

Pancreatic Cancer Stage IV | Pancreatic Cancer Stage III

China
Fudan University

Recruiting

Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)

Diabete Mellitus | Pancretic Cancer

China
Shanghai Juncell Therapeutics
Shanghai 10th People's Hospital

Recruiting

Study on TIL for the Treatment of Advanced Hepatobiliary-Pancreatic Cancers

Treatment Side Effects | Effects of Immunotherapy | Advanced Liver Cancers | Tumor Infiltrating Lymphocyte | Advanced Pancreatic Cancers

China
RenJi Hospital

Recruiting

A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV

China
Fudan University

Unknown

Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection

Stage ⅠA Pancreatic Cancer | Stage ⅠB Pancreatic Cancer | Stage ⅡA Pancreatic Cancer | Stage ⅡB Pancreatic Cancer

China
Changhai Hospital

Recruiting

Implantation of iodine125-Seeds Combined With Chemotherapy in the Treatment of Metastatic Pancreatic Carcinoma

Metastatic Pancreatic Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Unknown

Divestment for Artery-involved Pancreatic Cancer

Pancreatic Cancer | Neoadjuvant Therapy | Borderline Resectable Pancreatic Cancer | Locally Advanced Pancreatic Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer (ATNPA)

Locally Advanced Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer | Pancreatic Neoplasm

China
Changhai Hospital

Recruiting

Statin Addition to Chemotherapy for Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Fudan University

Not yet recruiting

Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients

Advanced Pancreatic Cancer

China
AIPING ZHOU

Completed

Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
CSPC Ouyi Pharmaceutical Co., Ltd.

Unknown

Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.

Advanced Pancreatic Cancer

China
Fudan University

Unknown

Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen

Metastatic Pancreatic Cancer

China
Chinese PLA General Hospital

Unknown

Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer (NAPSPAC)

Advanced Pancreatic Cancer

China
Fudan University

Recruiting

AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Cancer

China
Rui-hua Xu, MD, PhD

Not yet recruiting

A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD

Advanced Pancreatic Cancer

China
Fudan University
Qilu Hospital of Shandong University; The Third Affiliated Hospital of Soochow...

Not yet recruiting

LRAMPS Versus LDP in Selected Early-stage Left-sided Pancreatic Cancer

Left-sided Pancreatic Cancer

China
Fudan University
West China Hospital; Tongji Hospital; Qilu Hospital of Shandong University; Zhejiang... and other collaborators

Recruiting

Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC

Borderline Resectable Pancreatic Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

IORT Versus CCRT for Pancreatic Cancer (IVCPC)

Pancreatic Cancer Stage IV

China
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Fudan University
CSPC Ouyi Pharmaceutical Co., Ltd.

Unknown

Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
Chinese PLA General Hospital

Unknown

Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer

Unresectable Pancreatic Cancer

China
Chinese PLA General Hospital

Unknown

Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer (NAPGAP)

Advanced Pancreatic Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer

Resectable Pancreatic Cancer

China
Fudan University

Not yet recruiting

A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen

Metastatic Pancreatic Cancer

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of Irinotecan Liposome in Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Fudan University

Unknown

Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
RenJi Hospital
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Prospective, Single-arm, Exploratory Clinical Study of Sintilimab Injection in Combination With Paclitaxel (Albumin-bound) and Gemcitabine in Translational Therapy in Patients With Unresectable Locally Advanced Pancreatic Cancer.

Unresectable Locally Advanced Pancreatic Cancer

China
Jiangsu Healthy Life Innovation Medical Technology...

Not yet recruiting

Clinical Study of Tumor Treating Fields Combined With Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Cancer

China
Shanghai Proton and Heavy Ion Center

Recruiting

Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer

Pancreatic Cancer Non-resectable

China
Peking University

Not yet recruiting

The Transformation of Locally Advanced Pancreatic Cancer.

Locally Advanced Pancreatic Cancer

China
RenJi Hospital
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR- 1210 Combined With Paclitaxel (Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer Stage IV

China
Peking Union Medical College Hospital

Unknown

Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Cancer

China
Peking Union Medical College Hospital

Unknown

Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

Borderline Resectable Pancreatic Cancer

China
Sizhen Wang
Shanghai Biomed-union Biotechnology Co., Ltd.

Recruiting

The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer

Advanced Pancreatic Cancer

China
The Affiliated Hospital of Xuzhou Medical University

Not yet recruiting

Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Zhejiang University

Recruiting

Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Yuhong Li

Completed

Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.

Pancreatic Cancer Resectable

China
Fuda Cancer Hospital, Guangzhou
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.

Withdrawn

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Fuda Cancer Hospital, Guangzhou
Shengxin Biotechnology Institute, Beijing

Completed

Bioinformation Therapy for Pancreatic Cancer

Unresectable Pancreatic Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Borderline Resectable Pancreatic Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Cancer

China
Changhai Hospital

Recruiting

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Advanced Cancer | Pancreatic Ductal Adenocarcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

First-line Treatment of Advanced Pancreatic Cancer

China
Changhai Hospital

Recruiting

Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer

Recurrent Pancreatic Cancer

China
Zhejiang Provincial People's Hospital
Hangzhou Neoantigen Therapeutics Co., Ltd.

Recruiting

Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

Resectable Pancreatic Cancer

China
Health Science Center of Xi'an Jiaotong University
Huazhong University of Science and Technology; LinkDoc Technology (Beijing)...

Recruiting

The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer

Pancreatic Cancer Resectable

China

Clinical Trials on Pancreatic Cancer in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations